公开(公告)号：US20230242569A1

公开(公告)日：2023-08-03

申请号：US18167772

申请日：2023-02-10

Applicant: Bristol-Myers Squibb Company ,  The Scripps Research Institute

Inventor： Michael Anthony SCHMIDT ,  Bin ZHENG ,  Kyle KNOUSE ,  Justine deGRUYTER ,  Martin D. EASTGATE ,  Phil BARAN ,  William R. EWING ,  Richard E. OLSON ,  Ivar M. MCDONALD

IPC: C07H21/00

CPC classification number: C07H21/00

Abstract: The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.

公开(公告)号：US20210180065A1

公开(公告)日：2021-06-17

申请号：US17165841

申请日：2021-02-02

Applicant: Bristol-Myers Squibb Company ,  Roche Innovation Center Copenhagen A/S

Inventor： Richard E. OLSON ,  Angela M. CACACE ,  Jere E. MEREDITH, JR. ,  Nino DEVIDZE ,  James K. LOY ,  Carl J. BALDICK ,  Annapurna PENDRI ,  Ivar M. McDONALD ,  Peter HAGEDORN ,  Marianne Lerbech JENSEN

IPC: C12N15/113

Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.

公开(公告)号：US20210378652A1

公开(公告)日：2021-12-09

申请号：US17303890

申请日：2021-06-09

Applicant: Bristol-Myers Squibb Company ,  Roche Innovation Center Copenhagen A/S

Inventor： Richard E. OLSON ,  Brian R. ANDERSON ,  Peter HAGEDORN ,  Marianne Lerbech JENSEN ,  Ivar M. MCDONALD ,  Stephen E. MERCER

IPC: A61B17/02 ,  A61F2/44 ,  A61B1/32

Abstract: The present disclosure relates to antisense oligonucleotides, which target CAMK2D mRNA in a cell, leading to reduced expression of CAMK2D protein. Reduction of CAMK2D protein expression is beneficial for the treatment of certain medical disorders, e.g., cardiovascular-related diseases or disorders.

公开(公告)号：US20190383797A1

公开(公告)日：2019-12-19

申请号：US15548390

申请日：2016-02-04

Applicant: Bristol-Myers Squibb Company ,  Roche Innovation Center Copenhagen A/S

Inventor： Richard E. OLSON ,  Angela M. CACACE ,  Peter HAGEDORN ,  Anja Mølhart HØG ,  Niels Fisker NIELSEN ,  Dong LI ,  Jeffrey M. BROWN ,  Stephen E. MERCER ,  Marianne Lerbech JENSEN

IPC: G01N33/50 ,  G01N33/53 ,  G01N33/68 ,  A61K49/00 ,  C12N15/113

Abstract: The present disclosure provides methods of using a calcium oscillation assay and/or a sequence score calculation to identify a molecule that is safe for administration. The disclosure also includes a method of selecting or identifying a molecule having tolerable in vivo neurotoxicity using a calcium oscillation assay, a sequence score method, an in vivo tolerability assay, or any combination thereof.

公开(公告)号：US20230193260A1

公开(公告)日：2023-06-22

申请号：US17815493

申请日：2022-07-27

Applicant: Bristol-Myers Squibb Company ,  Roche Innovation Center Copenhagen A/S

Inventor： Richard E. OLSON ,  Angela M. Cacace ,  Jere E. Meredith, JR. ,  Nino Devidze ,  James K. Loy ,  Carl J. Baldick ,  Annapurna Pendri ,  Ivar M. McDonald ,  Peter Hagedorn ,  Marianne Lerbech Jensen

IPC: C12N15/113

CPC classification number: C12N15/113 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/351 ,  C12N2310/3231

Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.

公开(公告)号：US20190322694A1

公开(公告)日：2019-10-24

申请号：US16382692

申请日：2019-04-12

Applicant: Bristol-Myers Squibb Company ,  The Scripps Research Institute

Inventor： Michael Anthony SCHMIDT ,  Bin ZHENG ,  Kyle KNOUSE ,  Justine deGRUYTER ,  Martin D. EASTGATE ,  Phil BARAN ,  William R. EWING ,  Richard E. OLSON ,  Ivar M. McDONALD

IPC: C07H21/00

Abstract: The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.

公开(公告)号：US20160237427A1

公开(公告)日：2016-08-18

申请号：US15016169

申请日：2016-02-04

Applicant: Bristol-Myers Squibb Company ,  Roche Innovation Center Copenhagen A/S

Inventor： Richard E. OLSON ,  Angela M. CACACE ,  Peter HAGEDORN ,  Anja Mølhart HØG ,  Marianne Lerbech JENSEN ,  Niels Fisker NIELSEN ,  Dong LI ,  Jeffrey M. BROWN ,  Stephen E. MERCER

IPC: C12N15/113

Abstract: The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.

Abstract translation: 本发明涉及靶向细胞中Tau mRNA的低聚物化合物（寡聚体），导致Tau蛋白的表达降低。 Tau蛋白表达的降低有利于治疗某些医学病症，例如神经障碍。

公开(公告)号：US20220213484A1

公开(公告)日：2022-07-07

申请号：US17594154

申请日：2020-04-02

Applicant: Bristol-Myers Squibb Company ,  Roche Innovation Center Copenhagen A/S

Inventor： Brian R. ANDERSON ,  Richard E. OLSON ,  Ivar M. MCDONALD ,  Stephen E. MERCER ,  Peter HAGEDORN ,  Marianne Lerbech JENSEN

IPC: C12N15/113

Abstract: The present disclosure relates to antisense oligonucleotides, which target ANGPTL2 mRNA in a cell, leading to reduced expression of ANGPTL2 protein. Reduction of ANGPTL2 protein expression is beneficial for the treatment of certain medical disorders, such as those associated with abnormal ANGPTL2 expression and/or activity e.g., cardiovascular-related diseases or disorders.

公开(公告)号：US20170129892A1

公开(公告)日：2017-05-11

申请号：US15317553

申请日：2015-06-05

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Ivar M. MCDONALD ,  Richard E. OLSON ,  Robert A. MATE

IPC: C07D471/18 ,  C07D519/00

CPC classification number: C07D471/18 ,  C07D519/00

Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

公开(公告)号：US20230089255A1

公开(公告)日：2023-03-23

申请号：US17786442

申请日：2020-12-18

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Susan WEE ,  Joseph L. BENC ,  Xinyu WANG ,  Upender VELAPARTHI ,  Louis S. CHUPAK ,  Chatan P. DARNE ,  Min DING ,  Robert G. GENTLES ,  Yazhong HUANG ,  Scott W. MARTIN ,  Ivar M. MCDONALD ,  Richard E. OLSON ,  Xiaofan ZHENG ,  John S. TOKARSKI ,  Bireshwar DASGUPTA ,  Manjunatha Narayana Rao KAMBLE ,  Raju MANNOORI ,  Haslbur RAHAMAN ,  Prasada Rao JALAGAM ,  Saumya ROY ,  Gopikishan TONUKUNURU ,  Sivasudar VELAIAH ,  Jayakumar Sankara WARRIER ,  Kotha Rathnakar REDDY ,  Thiruvenkadam RAJA ,  Denise GRUNENFELDER ,  Michael WICHROSKI

IPC: A61K31/519 ,  A61K31/496 ,  A61K39/395 ,  A61P35/00

Abstract: Provided are inhibitors of diacylglycerol kinases (DGK) and methods for treating diseases that would benefit from the stimulation of the immune system, such as cancer and infections diseases, comprising administering a DGK inhibitor in combination with an antagonist of the PD 1/PD-L 1 axis and/or an antagonist of CTLA4.